A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Preladenant (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 01 Mar 2018 Status changed from recruiting to discontinued as the data did not support study endpoints
- 26 Jun 2017 Planned End Date changed from 26 Oct 2020 to 8 Jul 2019.
- 26 Jun 2017 Planned primary completion date changed from 26 Oct 2020 to 8 Jul 2019.